CERBA-RESEARCH
24.8.2021 14:03:02 CEST | Business Wire | Press release
Cerba Research , a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.
This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
The expansion includes investments in a new facility in Taipei (Taiwan) and state-of-the-art technologies to strengthen capabilities and services offered to our clients on a truly global scale:
- Cutting-edge flow cytometry technologies
- Exploratory as well as In Vitro Diagnostic histopathology services
- Peripheral blood mononuclear cell (PBMC) isolations from blood and soft tissues
Progress on construction, technology transfers, and expansion of the scientific team will enable the CerbACT Asia Laboratory to be fully operational in September 2021.
Mario Papillon, CEO of Cerba Research comments: “This milestone with ACT Genomics validates our innovative history as a company. We will support our customers with the latest instrumentation and automation — backed by experienced scientists whose ambition and agility to meet patients’ needs drive our continuous evolution as a company.”
“We are excited to create a partnership with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication in the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine,” says Hua Chien Chen, CEO, ACT Genomics.
About Cerba Research
Cerba Research is a leading healthcare company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization. Providing early phase research, clinical development through central laboratory and diagnostic services, assay and biomarker development and validation. Working with government agencies, non-government organizations as well as pharma and biotech organizations to change the shape of clinical development. Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis.
About ACT Genomics
ACT Genomics is an innovation-driven cancer solution provider in Asia with offices in Taipei, Hong Kong, Singapore, Tokyo, and Wales (U.K.). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we “Turn Genomics into Action.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005259/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
NIQ and Similarweb Advance Agentic Commerce Measurement for the AI Shopping Era2.9.2026 12:45:00 CEST | Press release
New solution will connect AI-driven discovery to consumer intent, product content, AI-driven traffic and sales conversion NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced further advancements in its Agentic Commerce Measurement strategy through a collaboration with Similarweb (NYSE: SMWB). The companies are collaborating on a new solution to help brands, retailers and technology platforms understand how products are purchased in an increasingly agentic economy. The work adds a measurement component to NIQ's Commerce Intelligence strategy, focused on deploying NIQ’s world-class, AI-ready content directly into agentic commerce workflows and equipping brands and retailers with the signals they need to react effectively. AI agents are moving beyond product discovery to become part of the purchase itself. New infrastructure, including Google's Universal Commerce Protocol and OpenAI's Agentic Commerce Protocol, is enabling consumers to complete the entire buying jour
MEX Exchange, part of MultiBank Group, Strengthens Global Operations and Technology Leadership with Three Senior Promotions2.9.2026 12:38:00 CEST | Press release
Jeremy Pearce and Beth White promoted to regional COO roles, with James Longo named CTO MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced three senior promotions as it strengthens its operational and technology leadership to support the continued development and international growth of its institutional trading business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902298207/en/ Jeremy Pearce has been promoted to COO – Middle East, Africa & Asia, Beth White to COO – Americas & Europe, and James Longo to Chief Technology Officer (CTO). Jeremy Pearce has been promoted to COO – Middle East, Africa & Asia, Beth White to COO – Americas & Europe, and James Longo to Chief Technology Officer (CTO). The appointments establish dedicated operational leadership across MEX Exchange’s key international markets, supported by experienced technology leadership as the company continues to devel
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree2.9.2026 12:30:00 CEST | Press release
Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Compass is leading a profound shift in the development of new treatment options in mental health care – moving beyond daily or frequent administration toward an option that could potentially provide durable efficacy with just a few treatments a year that could be life changing for patients. Supported by robust clinical data from three late-stage trials involving more than 1,000 participants living with treatment-resistant depression (TRD), COMP360 psilocybin, if approved by the U.S. Food & Drug Administration (FDA), has the potential to establish a new standard of care for a condition affectin
Exeon Analytics expands management team for next growth phase2.9.2026 10:00:00 CEST | Press release
Exeon Analytics is expanding its management team with two new roles. Wayne Jennings takes on the newly created position of Chief Solutions Officer, and Johan Roman becomes Chief Revenue Officer. The appointments fall in the company’s anniversary year, ten years after its founding as an ETH Zurich spin-off, and create the structure for the next growth phase. Exeon Analytics delivers holistic security analytics for organizations facing growing blind spots, encrypted traffic and regulatory pressure. Wayne Jennings joined Exeon Analytics in July 2024 and initially led Support and Engineering. As Chief Solutions Officer, he is responsible for the technical customer lifecycle, from pre-sales and proof of concept through implementation to long-term technical account management, and for the technical enablement of partners. Before joining Exeon Analytics, he was a Senior Manager in Cybersecurity & Privacy at PwC Switzerland, focusing on threat intelligence and incident response. Johan Roman br
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom